PER 1.23% 8.0¢ percheron therapeutics limited

EQUITY RESEARCH REPORT - WILSON dated 18 Jan 2022, page-120

  1. 69 Posts.
    lightbulb Created with Sketch. 51
    Just thinking out loud and trying to think (rate management higher than they deserve???)...
    Does anyone think the company might have taken advantage of the high SP and screwed over the instos on purpose?

    There will need to be another CR, but they did get a premium price from the instos based on the current SP. Is there another play from management, that we don't know about, coming??
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.